Valuation: H. Lundbeck A/S

Capitalization 42.14B 6.58B 5.64B 5.27B 4.93B 9.17B 591B 9.94B 61.88B 23.88B 279B 24.69B 24.16B 1,018B P/E ratio 2025 *
11.3x
P/E ratio 2026 * 10.1x
Enterprise value 50.82B 7.93B 6.8B 6.36B 5.94B 11.06B 713B 11.98B 74.63B 28.8B 337B 29.77B 29.14B 1,228B EV / Sales 2025 *
2.07x
EV / Sales 2026 * 1.85x
Free-Float
30.74%
Yield 2025 *
2.81%
Yield 2026 * 3.1%
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.88%
1 week+1.13%
Current month+1.13%
1 month-2.56%
3 months+8.40%
6 months+16.98%
Current year+8.71%
More quotes
1 week 43.68
Extreme 43.68
44.94
1 month 42.56
Extreme 42.56
47.16
Current year 27.2
Extreme 27.2
47.78
1 year 27.2
Extreme 27.2
47.78
3 years 25.12
Extreme 25.115
49.38
5 years 23.3
Extreme 23.295
49.38
10 years 23.3
Extreme 23.295
49.38
More quotes
Manager TitleAgeSince
Chief Executive Officer 58 2023-09-30
Director of Finance/CFO 48 2022-08-31
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 66 2015-03-24
Director/Board Member 66 2015-03-24
Director/Board Member 59 2018-03-19
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.88%+1.13%+1.31%+66.80% 6.58B
+1.09%-7.87%+33.04%+110.46% 100B
-0.26%-6.54%+59.05%+146.28% 47.33B
+3.26%-1.04% - - 21.01B
-0.40%+2.62%+14.08%+1.70% 10.49B
-0.22%+0.45%-16.28%-6.19% 8.48B
+0.49%+2.59%+0.29%+10.42% 8.2B
+0.24%+1.10%+21.65%+28.97% 5.72B
-2.63%-2.75%+10.23%+52.91% 3.6B
+0.40%+3.25%-4.15%+0.07% 3.58B
Average +0.22%-0.97%+13.24%+45.72% 21.55B
Weighted average by Cap. +0.45%-5.31%+32.30%+97.03%
See all sector performances

Financials

2025 *2026 *
Net sales 24.53B 3.83B 3.28B 3.07B 2.87B 5.34B 344B 5.78B 36.02B 13.9B 162B 14.37B 14.06B 592B 25.18B 3.93B 3.37B 3.15B 2.94B 5.48B 353B 5.94B 36.97B 14.27B 167B 14.75B 14.43B 608B
Net income 3.89B 607M 521M 487M 455M 847M 54.56B 918M 5.71B 2.21B 25.78B 2.28B 2.23B 94.01B 4.36B 681M 584M 546M 510M 950M 61.19B 1.03B 6.41B 2.47B 28.91B 2.56B 2.5B 105B
Net Debt 8.68B 1.35B 1.16B 1.09B 1.01B 1.89B 122B 2.05B 12.75B 4.92B 57.51B 5.09B 4.98B 210B 4.47B 698M 599M 560M 523M 973M 62.7B 1.05B 6.57B 2.53B 29.62B 2.62B 2.56B 108B
More financial data * Estimated data
Logo H. Lundbeck A/S
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,700
More about the company
Date Price Change Volume
25-12-05 44.92 kr +0.94% 145,580
25-12-04 44.50 kr +1.09% 228,263
25-12-03 44.02 kr -0.68% 332,435
25-12-02 44.32 kr +1.23% 294,344
25-12-01 43.78 kr -1.44% 578,739

Delayed Quote Nasdaq Copenhagen, December 05, 2025 at 09:12 am

More quotes
Trader
Investor
Global
Quality
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
11
Last Close Price
44.50DKK
Average target price
48.59DKK
Spread / Average Target
+9.19%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. HLUN B Stock